# VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib

> **NCT03400176** · PHASE1 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 39 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia (CLL)

## Interventions

- **DRUG:** VAY736
- **DRUG:** ibrutinib

## Key facts

- **NCT ID:** NCT03400176
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-04-09
- **Primary completion:** 2023-09-29
- **Final completion:** 2023-09-29
- **Target enrollment:** 39 (ACTUAL)
- **Why stopped:** Business reasons
- **Last updated:** 2025-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03400176

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03400176, "VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03400176. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*